The price of innovation: new estimates of drug development costs.

Keywords

Business, Point (geometry), Total cost, Economics, Actuarial science

References

• Competitive Strategies in the Pharmaceutical IndustryRobert B. Helms — 1996
• Stocks, bonds, bills, and inflation yearbookIbbotson Associates — 1993
• The Contribution of Pharmaceutical Companies: What's at Stake for AmericaERAN BROSHY — 1994
• The link between gross profitability and pharmaceutical R&D spending.F. M. Scherer — 2001
• R&d Costs, Innovative Output and Firm Size in the Pharmaceutical IndustryJoseph A. DiMasi, Henry G. Grabowski, John M. Vernon — 1995
• The New Drug Approvals of 1996, 1997, & 1998: Drug Development Trends in The User Fee EraKenneth I. Kaitin, Elaine M. Healy — 1999
• Returns to R&D on new drug introductions in the 1980s.Henry G. Grabowski, John M. Vernon — 1994
• Issues in pharmaceutical economicsHenry B. Steele, Robert Chien — 1979
• Risks in new drug development: Approval success rates for investigational drugsJoseph A. DiMasi — 2001
• New drug development in the United States from 1963 to 1999Joseph A. DiMasi — 2001
• Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 1995
• New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical FirmsJoseph A. DiMasi — 2000
• Measuring the Pace of New Drug Development in the User Fee ERAKenneth I. Kaitin, Joseph A. DiMasi — 2000
• A New Look at the Returns and Risks to Pharmaceutical R&DHenry G. Grabowski, John M. Vernon — 1990
• New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.Janice M. Reichert — 2000
• Cost of innovation in the pharmaceutical industry.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 1991
• Drug development: improving the process.Peck Cc — 1997
• Intangible Capital and Rates of Returnkenneth-w-clarkson — 1977
• The Pharmaceutical IndustryD. Belk, P. Belk — 1965
• The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee EraKenneth I. Kaitin, Elaine M. Healy — 2000

Cited by

• Should the Increase in Military Pay Be SlowedJames Hosek, Beth J. Asch, Michael G. Mattock — 2012
• Intellectual property rights and research disclosure in the university environment: preserving the commercialization option and optimizing market interest.Robert Patino — 2009
• Biomarkers for chronic pain and analgesia. Part 2: how, where, and what to look for using functional imaging.David Borsook, Lino Becerra, Richard Hargreaves — 2011
• Financial Analysts impact on Stock VolatilityClara Isabel González Martínez, Ricardo Gimeno — 2012
• New insights into public perceptions of cancerCorina W Ramers-Verhoeven, Gary Geipel, Moira Howie — 2013
• Financing Drug Research: What are the Issues?Dean C. Baker — 2008
• Current trends in modern pharmaceutical analysis for drug discovery.Eduardo Abad Valdenebro, José María Cobos Gómez — 2003
• Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry.James A. Tompkins — 2004
• Imatinib mesylate for melanoma: will a new target be revealed?Douglas Grossman — 2004
• Role of pharmacoeconomic analysis in R&D decision makingKristina Ängeby Möller — 2005
• Study design and rationale of a mock phase I trial as an educational tool for clinical pharmacology residents.Susana Le Brech, Marta Amat, Tomàs Camps — 2006
• New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.Andrew W. Lo, Sourya V. Naraharisetti — 2013
• Applying the concepts of financial options to stimulate vaccine developmentVanessa Rato — 2006
• Value of pharmaceuticals: ensuring the future of research and development.Hamida K. Serajuddin, Abu T.M. Serajuddin — 2006
• The market for follow-on biologics: how will it evolve?Henry G. Grabowski, Iain Cockburn, Genia Long — 2006
• Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update.Manuel Titos Martínez — 2007
• Johnny’s in the Basement, Mixin’ Up the Medicine奈利子 松田 — 2007
• Predicting Human Hepatic Clearance Using Hypernet Neural NetworksShahab Sheikh-Bahaei, Kamran A. Ali, Sabina R. Bera — 2010
• Microscale granulation in a fluid bed powder processor using electrostatic atomisation.L. Abdelkhalek, Mohamed Afellah, C. Smaili — 2009
• From off-label prescribing towards a new FDA.Alain Pigeard — 2009

Related papers

• Fiscal Policy and the Terms of Trade in an Analytical Two-Country Dynamic ModelMarcelo Bianconi — 2003
• Monetary-fiscal policy interactions and the price level:Background and beyondEric M. Leeper, Tack Yun — 2006
• Unemployment as excess supply of labor: Implications for wage and price inflationMiguel Casares — 2010
• Stabilisation, Policy Targets and Unemployment in Imperfectly Competitive EconomiesGeorge J. Bratsiotis, Christopher Martin — 1999
• The macroeconomic impact of the nixon wage and price controls: A general equilibrium approachLawrence Davidson — 1983
• Fiscal and exchange rate policies in a fix-price trade model with export rationingJohn T. Cuddington — 1980
• Welfare costs of inflation in a dynamic economy with search unemploymentBurkhard Heer — 2002
• Macroeconomic priorities revisited: the behavioural foundations of stabilization policiesFabio D’Orlando, Francesco Ferrante — 2018
• Robustness of multiple equilibria in OLG economiesGuido Cazzavillan, Patrick Pintus — 2004